Key Highlights
- Dr. Dipanjan Chowdhury joins BPGbio’s Advisory Board.
- Expertise in translational cancer research to enhance preclinical and clinical processes.
- Focus on mitochondrial biology and protein homeostasis.
- Advancing therapies for aggressive solid tumors.
- BPGbio’s NAi platform targets novel pathways for cancer treatment.
Source: Business Wire
Notable Quotes
- “The team at BPGbio is at the forefront of advancing medicines on highly aggressive cancer phenotypes through their pioneering work in mitochondrial biology and protein homeostasis. I look forward to contributing to the company’s innovative efforts and helping to drive forward BPGbio’s mission of developing breakthrough therapies for patients with unmet needs.” — Dr. Dipanjan Chowdhury, Chief of the Division of Radiation and Genome Stability at Dana-Farber Cancer Institute
- “It’s a privilege to have Dr. Chowdhury join our Scientific Advisory Board. His expertise in translational cancer research related to proteins will be very valuable in helping us perfect our target validation process.” — Niven R. Narain, Ph.D., Chairman, President and CEO at BPGbio
SoHC's Take
The appointment of Dr. Dipanjan Chowdhury to BPGbio’s Advisory Board is a strategic move that underscores the company’s commitment to advancing cancer therapies through innovative research. Dr. Chowdhury’s expertise in DNA damage repair mechanisms and his pioneering work in understanding protein roles in genomic stability are invaluable assets. This collaboration promises to enhance BPGbio’s capability to develop groundbreaking treatments, particularly for aggressive solid tumors. The integration of Dr. Chowdhury’s insights with BPGbio’s AI-driven NAi platform could potentially unlock new avenues in cancer therapy, making significant strides in targeting undruggable pathways and improving patient outcomes.
